Article
Lack of relevance of the acetylator status on dapsone response in chronic autoimmune thrombocytopenic purpura.
American journal of hematology - 1 Dec 1999
Le Louët H, Ruivart M, Bierling P, Duche J C, Godeau B
Abstract excerpt
Dapsone provides an alternative treatment for patients with chronic autoimmune thrombocytopenic purpura (AITP) who had inadequate response to conventional therapy. However, the efficacy of this treatment is achieved in only 50% of patients. Dapsone is partly metabolized by the polymorphic N-acetyltransferase 2% and 50% of Caucasian patients show a genetically determined slow acetylator phenotype. The aim of our...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.